NCT02671162

Evaluating the Effect of Fumaria Parviflora L. in Uremic Pruritus

Evaluation the Effect of Fumaria Parviflora L. on Uremic Pruritus of End-stage Renal Disease Patients: A Randomized Double- Blind Placebo-controlled Clinical Trial

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 63 (actual)
• Sponsor: Shiraz University of Medical Sciences · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether Fumaria Parviflora L. can minimize severity of pruritus in patients with end-stage renal disease.

Detailed description

Uremic Pruritus is still a common complication in end-stage renal disease patients. The pathogenesis of Uremic Pruritus is unknown, therefore treatments are ineffective. According to several studies Uremic Pruritus is not an isolated skin disease. It seems to be a systemic inflammatory disease with a deranged balance of T helper cell differentiation. In this study investigators considered to evaluate effect of Fumaria Parviflora L. in uremic pruritus by a double blind placebo control clinical trial. It is hypothesized that oral Fumaria Parviflora L. may minimize uremic pruritus by decreasing serum Interferon gamma (IFN-γ) and high-sensitive C reactive protein (hs-CRP).

Conditions

• End-Stage Renal Disease
• Pruritus

Interventions

Type	Name	Description
DRUG	Wheat	3 times a day each time 2 capsules before eating meal for 8 weeks.
DRUG	Fumaria	3 times a day each time 2 capsules before eating meal for 8 weeks.

Timeline

• Start date: 2015-07-01
• Primary completion: 2015-10-01
• Completion: 2016-01-01
• First posted: 2016-02-02
• Last updated: 2016-02-02